Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

0.7420 +0.0061 (+0.83%)
Streaming Delayed Price Updated: 12:58 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
Insights Ahead: Skye Bioscience's Quarterly Earnings ↗
 
Via Benzinga
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
US Stocks Mixed; Dow Falls 100 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss ↗
Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results. 
Via Benzinga
News headline image
Monday's session: gap up and gap down stocks ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million. 
Via Benzinga
News headline image
Could This New Drug Be The Safer Way To Fight Obesity? ↗
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies. 
Via Benzinga
News headline image
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗
Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk. 
Via Benzinga
News headline image
Skye (SKYE) Q2 R&D Soars 249% No Revenue ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Which stocks have an unusual volume on Tuesday? 
Via Chartmill
News headline image
What's going on in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
News headline image
Top stock movements in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.